Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Faehling, Martin, Schumann, Christian, Christopoulos, Petros, Hoffknecht, Petra, Alt, Jürgen, Horn, Marlitt, Eisenmann, Stephan, Schlenska-Lange, Anke, Schütt, Philipp, Steger, Felix, Brückl, Wolfgang M., Christoph, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750486/
https://www.ncbi.nlm.nih.gov/pubmed/33364266
http://dx.doi.org/10.1016/j.dib.2020.106556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750486/
https://www.ncbi.nlm.nih.gov/pubmed/33364266
http://dx.doi.org/10.1016/j.dib.2020.106556

Ejemplares similares